Zentalis appoints Luke Walker, M.D. to board, expanding to 7 directors

Zentalis Pharmaceuticals, Inc.

Board increased from 6 to 7 members; Dr. Walker appointed as Class II director effective May 24, 2024.
Term runs until 2025 annual meeting; Dr. Walker also joins Audit Committee.
Initial RSU grant of 72,481 shares valued at $850,000, vesting over 3 years.
Annual retainer for board service $45,000 plus $10,000 for Audit Committee membership.
Standard indemnification agreement signed; annual equity grants after 6 months service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Luke Walker, M.D.

Director

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2024-05-24
Filed: May 29, 2024, 7:59 PM ET

On and effective May 24, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Luke Walker, M.D., as a Class II director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Luke Walker, M.D. was appointed as Director at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

On and effective May 24, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Luke Walker, M.D., as a Class II director.

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-24-000120

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.